Details for Patent: 9,566,290
✉ Email this page to a colleague
Title: | Boron-containing small molecules |
Abstract: | This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. |
Inventor(s): | Baker; Stephen J. (Collegeville, PA), Akama; Tsutomu (Sunnyvale, CA), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Maples; Kirk (San Jose, CA), Plattner; Jacob J. (Berkeley, CA), Sanders; Virginia (San Francisco, CA), Zhang; Yong-Kang (San Jose, CA), Fieldson; Gregory T. (Morgantown, WV), Leyden; James J. (Malvern, CA) |
Assignee: | Anacor Pharmaceuticals, Inc. (Palo Alto, CA) |
Filing Date: | Apr 20, 2016 |
Application Number: | 15/134,286 |
Claims: | 1. A method of treating a human having onychomycosis of a toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes, the method comprising: topically administering to the toenail a pharmaceutical composition comprising an amount of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof, effective to inhibit an aminoacyl tRNA synthetase in the Trichophyton rubrum or Trichophyton mentagrophytes. 2. The method of claim 1, wherein the pharmaceutical composition is in the form of a solution comprising 5% w/w of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the pharmaceutical composition further comprises ethanol and propylene glycol. 4. The method of claim 1, wherein the aminoacyl tRNA synthetase is leucyl tRNA synthetase. 5. The method of claim 4, wherein the pharmaceutical composition is in the form of a solution comprising 5% w/w of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof. 6. The method of claim 5, wherein the pharmaceutical composition further comprises ethanol and propylene glycol. 7. The method of claim 1, wherein the administering of the pharmaceutical composition occurs once a day. 8. The method of claim 6, wherein the administering of the pharmaceutical composition occurs once a day. 9. The method of claim 1, wherein the method inhibits an aminoacyl tRNA synthetase in Trichophyton rubrum. 10. The method of claim 1, wherein the method inhibits an aminoacyl tRNA synthetase in Trichophyton mentagrophytes. 11. The method of claim 6, wherein the method inhibits leucyl tRNA synthetase in Trichophyton rubrum. 12. The method of claim 6, wherein the method inhibits leucyl tRNA synthetase in Trichophyton mentagrophytes. |